Skip to search formSkip to main contentSkip to account menu

SKI-606

Known as: SKI 606, SKI606 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

bosutinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical activity and acceptable tolerability in… 
Highly Cited
2013
Highly Cited
2013
Functional human sperm capacitation requires both bicarbonate-dependent PKA activation and down-regulation of Ser/Thr phosphatases by Src family kinases.
In all mammalian species studied so far, sperm capacitation correlates with an increase in protein tyrosine (Tyr) phosphorylation… 
Highly Cited
2011
Highly Cited
2011
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
PurposeBosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, is in clinical development for the treatment of patients… 
Review
2010
Review
2010
Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.
2009
2009
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
Recently, Src tyrosine kinase has emerged as an attractive target for anticancer therapy, and Src is overexpressed in pancreatic… 
Highly Cited
2008
Highly Cited
2008
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
Imatinib mesylate (imatinib) is highly effective in the treatment of chronic myeloid leukemia (CML) but is less effective in… 
Highly Cited
2008
Highly Cited
2008
Src inhibition ameliorates polycystic kidney disease.
Despite identification of the genes responsible for autosomal dominant polycystic kidney disease (PKD) and autosomal recessive… 
Highly Cited
2006
Highly Cited
2006
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.
Inhibition of deregulated protein tyrosine kinases represents an attractive strategy for controlling cancer growth. However… 
Highly Cited
2006
Highly Cited
2006
A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia…
SKI-606 is an orally available, dual Src/Abl kinase inhibitor shown to be 200-fold more potent than imatinib as an inhibitor of… 
Highly Cited
2005
Highly Cited
2005
3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)